Sign Up Today and Learn More About Genialis Stock
Invest in or calculate the value of your shares in Genialis or other pre-IPO companies through EquityZen's platform.
Genialis Stock
Genialis is a computational precision medicines company that develops a clinical biomarker discovery platform.
About Genialis Stock
Founded
2015
Headquarters
Boston, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Genialis Press Mentions
Stay in the know about the latest news on Genialis
Next-Generation Sequencing (NGS) Data Analysis Market to Hit USD 4.21 Billion by 2032, Driven by Rising Genomic Research and Precision Medicine Initiatives – SNS Insider
globenewswire • Apr 26, 2025
Genialis Highlights Power of Its Supermodel to Predict and Explain Therapeutic Response at AACR 2025
biospace • Apr 24, 2025
Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago
biospace • Apr 23, 2025
Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago
businesswire • Apr 22, 2025
Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago
morningstar • Apr 22, 2025
Genialis Management
Leadership team at Genialis
CEO
Rafael Rosengarten
Chief Discovery Officer
Luka Ausec
Join now and verify your accreditation status to gain access to:
- Genialis Current Valuation
- Genialis Stock Price
- Genialis Management
- Available deals in Genialis and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Genialis Cap Table and Funding History by Share Class and Liquidity Preferences
- Genialis Revenue and Financials
- Genialis Highlights
- Genialis Business Model
- Genialis Risk Factors
- Genialis Research Report from SACRA Research
Trading Genialis Stock
How to invest in Genialis stock?
Accredited investors can buy pre-IPO stock in companies like Genialis through EquityZen funds. These investments are made available by existing Genialis shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Genialis stock?
Shareholders can sell their Genialis stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
